Incidence of Acute Kidney Injury in Trough and AUC/MIC Vancomycin Dosing Strategies in a Large Tertiary Care Center: A Retrospective Cohort
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6130 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Rafael Ruiz-Gaviria und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Infectious Disease Section, Medstar Washington Hospital Center, Washington, DC, USA. Hauptthemen laut MEDLINE: Vancomycin, Acute Kidney Injury, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Acute kidney injury (AKI) is a complication associated with vancomycin use. There is evidence that this was related to the presence of supratherapeutic vancomycin levels rather than the drug itself. The area under the curve over 24 h to minimum inhibitory concentration (AUC/MIC) dosing for vancomycin has replaced trough‐based dosing, but the impact of this change on AKI rates remains unclear. A retrospective cohort study was conducted in a tertiary care teaching hospital. Patients from the trough cohort were recruited from January 1, 2019, to June 30, 2019, and the AUC/MIC cohort from July 1, 2021, to January 1, 2022. Sociodemographics, clinical characteristics, and concomitant medications were obtained. AKI was defined by The Kidney Disease Improving Global Outcomes. A total of 1056 patients were included, 509 in the trough cohort and 547 in the AUC/MIC cohort. The baseline rates of chronic kidney disease were 15.4% and 9.9%, respectively. The AKI rates were 15.9% and 11.9% for trough and AUC/MIC cohorts, respectively ( P ‐value .045). The most frequent nephrotoxins were piperacillin/tazobactam (TZP), diuretics, and IV contrast for both groups. The rates of supratherapeutic levels were higher in the trough cohort (20.7%) than in the AUC/MIC cohort (6.6%). The multivariate logistic regression analysis showed that trough dosing was not associated with increased rates of AKI (OR = 0.96 CI 0.64‐1.44). Supratherapeutic levels (OR = 4.64), diuretics (OR = 1.62), TZP (OR = 2.01), and ICU admission (OR = 1.72) were associated with AKI. Vancomycin AUC/MIC dosing strategy was associated with decreased rates of supratherapeutic levels of this drug compared to trough dosing, with a trend toward lower rates of AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Infectious Disease Section, Medstar Washington Hospital Center, Washington, DC, USA.
- Department of Pharmacy, Medstar Washington Hospital Center, Washington, DC, USA.
- Medstar Health Research Institute, Hyattsville, MD, USA.
ORCID-Profile: Rafael Ruiz-Gaviria
Zitieren
APA
Ruiz-Gaviria, R., Norman, S. J., Elgendi, S. H., Chou, J., & Ramdeen, S. (2025). Incidence of Acute Kidney Injury in Trough and AUC/MIC Vancomycin Dosing Strategies in a Large Tertiary Care Center: A Retrospective Cohort. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6130
Vancouver
Ruiz-Gaviria R, Norman SJ, Elgendi SH, Chou J, Ramdeen S. Incidence of Acute Kidney Injury in Trough and AUC/MIC Vancomycin Dosing Strategies in a Large Tertiary Care Center: A Retrospective Cohort. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6130
BibTeX
@article{RuizGaviria2025,
author = {Ruiz-Gaviria, Rafael and Norman, Sarah J and Elgendi, Sarah H and Chou, Jiling and Ramdeen, Sheena},
title = {Incidence of Acute Kidney Injury in Trough and AUC/MIC Vancomycin Dosing Strategies in a Large Tertiary Care Center: A Retrospective Cohort},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6130}
}
EUVIMED